JP2003529542A - 癌の治療のためのエトドラクの使用 - Google Patents

癌の治療のためのエトドラクの使用

Info

Publication number
JP2003529542A
JP2003529542A JP2001511882A JP2001511882A JP2003529542A JP 2003529542 A JP2003529542 A JP 2003529542A JP 2001511882 A JP2001511882 A JP 2001511882A JP 2001511882 A JP2001511882 A JP 2001511882A JP 2003529542 A JP2003529542 A JP 2003529542A
Authority
JP
Japan
Prior art keywords
etodolac
cells
cancer
viability
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001511882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003529542A5 (enExample
Inventor
エー． カーソン，デニス
ビー． コッタム，ハワード
ソウイチ アダチ
エム． レオニ，ロレンツォ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/360,020 external-priority patent/US6545034B1/en
Application filed by University of California filed Critical University of California
Publication of JP2003529542A publication Critical patent/JP2003529542A/ja
Publication of JP2003529542A5 publication Critical patent/JP2003529542A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2001511882A 1999-07-23 2000-07-13 癌の治療のためのエトドラクの使用 Pending JP2003529542A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/360,020 1999-07-23
US09/360,020 US6545034B1 (en) 1999-07-23 1999-07-23 Use of etodolac for the treatment of chronic lymphocytic leukemia
US09/589,476 2000-06-07
US09/589,476 US7105560B1 (en) 1999-07-23 2000-06-07 Use of etodolac in the treatment of multiple myeloma
PCT/US2000/040370 WO2001006990A2 (en) 1999-07-23 2000-07-13 Use of etodolac to treat cancer

Publications (2)

Publication Number Publication Date
JP2003529542A true JP2003529542A (ja) 2003-10-07
JP2003529542A5 JP2003529542A5 (enExample) 2007-10-04

Family

ID=27000719

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001511882A Pending JP2003529542A (ja) 1999-07-23 2000-07-13 癌の治療のためのエトドラクの使用

Country Status (8)

Country Link
US (1) US7105560B1 (enExample)
EP (1) EP1204412A4 (enExample)
JP (1) JP2003529542A (enExample)
AU (1) AU785089B2 (enExample)
CA (1) CA2378371A1 (enExample)
IL (1) IL147748A0 (enExample)
NO (1) NO20020358L (enExample)
WO (1) WO2001006990A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014111642A (ja) * 2005-02-03 2014-06-19 Topotarget Uk Ltd Ｈｄａｃ阻害剤を用いる併用療法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
PT1104297E (pt) 1998-07-09 2006-05-31 Cephalon Inc Composicoes para o tratamento da leucemia linfocitica cronica
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US7129262B2 (en) 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7361680B2 (en) * 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7151100B1 (en) 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
WO2004026116A2 (en) 2002-09-19 2004-04-01 The Regents Of The University Of California Use of etodoclac to treat hyperplasia
ITMI20031471A1 (it) 2003-07-18 2005-01-19 Chemi Spa Processo per la racemizzazione dell'acido etodolico
US7461048B2 (en) * 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US7467119B2 (en) * 2003-07-21 2008-12-16 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
MXPA06003758A (es) * 2003-10-02 2006-08-11 Cephalon Inc Derivados de indol substituido.
WO2005050563A2 (en) 2003-11-17 2005-06-02 Aureon Biosciences Corporation Pathological tissue mapping
EP1728210A2 (en) * 2004-02-27 2006-12-06 Aureon Laboratories, Inc. Methods and systems for predicting occurrence of an event
EP1789923A1 (en) 2004-08-11 2007-05-30 Aureon Laboratories, Inc. Systems and methods for automated diagnosis and grading of tissue images
ITMI20060894A1 (it) 2006-05-05 2007-11-06 Univ Catania Ciclodestrine funzionalizzate con etodolac come agenti di rilascio sito specifico

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5638594B1 (enExample) * 1971-06-01 1981-09-08
WO1997003667A1 (en) * 1995-07-19 1997-02-06 Merck & Co., Inc. Method of treating colonic adenomas
WO1998019649A2 (en) * 1996-11-05 1998-05-14 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
WO1998040078A1 (en) * 1997-03-11 1998-09-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
JPH11502199A (ja) * 1995-03-13 1999-02-23 ロマ リンダ ユニバーシティ メディカル センター 大腸ガンの治療のための防護組成物中のｒ−ｎｓａｉｄの使用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL107185C (enExample) 1957-12-19
US3843480A (en) 1963-08-28 1974-10-22 D Dreher Dry dry transfer
US3948262A (en) 1969-04-01 1976-04-06 Alza Corporation Novel drug delivery device
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3974179A (en) 1971-06-01 1976-08-10 American Home Products Corporation 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetamides and derivatives
US3939178A (en) 1971-06-01 1976-02-17 American Home Products Corporation Certain pyrano [3,4-b]indoles and thiopyrano[3,4-b]indoles
US3948254A (en) 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
DE2226703A1 (de) 1972-05-25 1973-12-13 Schering Ag Neue tetrahydrocarbazolderivate und verfahren zu ihrer herstellung
US4041169A (en) 1975-03-05 1977-08-09 Ayerst Mckenna And Harrison Ltd. Pharmaceutical method for using pyrano-and thiopyranoindole derivatives
US4179503A (en) 1978-05-08 1979-12-18 American Home Products Corp. 1-Hydroxyalkanamine pyrano[3,4-b]indole derivatives
US4337760A (en) 1978-10-13 1982-07-06 Adolf Schwimmer Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals
US4310509A (en) 1979-07-31 1982-01-12 Minnesota Mining And Manufacturing Company Pressure-sensitive adhesive having a broad spectrum antimicrobial therein
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
JPS5777617A (en) 1980-10-20 1982-05-15 Nichiban Co Ltd Plaster for cardiac disease
IL61721A (en) 1980-12-16 1984-03-30 Blank Izhak Nitroglycerin preparations
US4542013A (en) 1981-07-08 1985-09-17 Key Pharmaceuticals, Inc. Trinitroglycerol sustained release vehicles and preparation therefrom
US4460562A (en) 1982-01-06 1984-07-17 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
US4485097A (en) 1982-05-26 1984-11-27 Massachusetts Institute Of Technology Bone-equivalent and method for preparation thereof
US4542012A (en) 1982-07-02 1985-09-17 Minnesota Mining And Manufacturing Company Film-forming composition containing an antimicrobial agent and methods
US4608249A (en) 1982-11-02 1986-08-26 Nitto Electric Industrial Co., Ltd. Hydrophilic therapeutic material
IT1153909B (it) 1982-12-17 1987-01-21 Sogimi Srl Polimeri reattivi per la cura di affezioni cutanee
GB8317576D0 (en) 1983-06-29 1983-08-03 Shaw A S W Consumer tobacco products
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4585877A (en) 1985-05-06 1986-04-29 American Home Products Corporation Process for preparing 1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)-indole-1-acetic acid, etodolac
GB8514665D0 (en) 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US4686213A (en) 1986-08-15 1987-08-11 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids
US4748252A (en) 1986-08-15 1988-05-31 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acids
CA1299577C (en) 1987-01-09 1992-04-28 John W. Gillard Tetrahydrocarbazole 1-alkanoic acids
EP0289262A3 (en) 1987-04-27 1989-05-31 Syntex Pharmaceuticals International Limited Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs
DE69328838T2 (de) 1992-03-13 2000-10-12 Sepracor Inc., Marlborough Antipyretische und analgetische verfahren und zusammensetzungen, die optisch reines r-etodolac enthalten
US5811558A (en) 1994-04-12 1998-09-22 Chiroscience Limited Process for the resolution of etodolac using glucamine derivatives
US6160018A (en) 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5981592A (en) 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US5599946A (en) 1995-05-30 1997-02-04 Teva Pharmaceutical Industries Ltd. 3-(2-trialkylsilyloxy)ethyl-7-ethyl-1H-indoles and method for their preparation
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
AU3641597A (en) 1996-06-21 1998-01-07 Advanced Research And Technology Institute, Inc. Methods and compositions comprising r-ibuprofen
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
US6054432A (en) 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
IE960761A1 (en) 1996-10-31 1998-05-06 Univ Dublin City Combinations for use in increasing the potency of a¹substrate for multidrug resistance related protein
US6552055B2 (en) * 1996-12-11 2003-04-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6110955A (en) 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Metabolically stabilized oxyalkylene esters and uses thereof
PT1104297E (pt) * 1998-07-09 2006-05-31 Cephalon Inc Composicoes para o tratamento da leucemia linfocitica cronica
US7197228B1 (en) 1998-08-28 2007-03-27 Monroe David A Multifunction remote control system for audio and video recording, capture, transmission and playback of full motion and still images
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
AUPQ849900A0 (en) 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
US20020042375A1 (en) 2000-07-05 2002-04-11 Heimbrook David C. Method of treating cancer
AU2001283224B2 (en) 2000-08-09 2007-06-28 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
WO2002085327A2 (en) 2001-04-18 2002-10-31 Oraltech Pharmaceuticals, Inc. Use of nsaids for prevention and treatment of cellular abnormalities of the female reproductive tract
US20030004142A1 (en) 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5638594B1 (enExample) * 1971-06-01 1981-09-08
JPH11502199A (ja) * 1995-03-13 1999-02-23 ロマ リンダ ユニバーシティ メディカル センター 大腸ガンの治療のための防護組成物中のｒ−ｎｓａｉｄの使用
WO1997003667A1 (en) * 1995-07-19 1997-02-06 Merck & Co., Inc. Method of treating colonic adenomas
WO1998019649A2 (en) * 1996-11-05 1998-05-14 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
WO1998040078A1 (en) * 1997-03-11 1998-09-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014111642A (ja) * 2005-02-03 2014-06-19 Topotarget Uk Ltd Ｈｄａｃ阻害剤を用いる併用療法

Also Published As

Publication number Publication date
CA2378371A1 (en) 2001-02-01
NO20020358L (no) 2002-03-21
WO2001006990A3 (en) 2001-04-26
AU785089B2 (en) 2006-09-14
IL147748A0 (en) 2002-08-14
EP1204412A4 (en) 2004-04-21
EP1204412A2 (en) 2002-05-15
AU7385900A (en) 2001-02-13
WO2001006990A2 (en) 2001-02-01
NO20020358D0 (no) 2002-01-23
US7105560B1 (en) 2006-09-12

Similar Documents

Publication Publication Date Title
US7105561B2 (en) Use of etodolac for the treatment of prostate cancer
JP2003529542A (ja) 癌の治療のためのエトドラクの使用
CA2294247C (en) Antioxidant enhancement of therapy for hyperproliferative conditions
KR20020031331A (ko) 미토콘드리아 관련 질환의 치료방법
JP2002520282A (ja) 慢性リンパ性白血病の処置のための方法および組成物
US5130145A (en) Pharmaceutical compositions with anit-cancer activity and method for the treatment of cancer
CA2459822C (en) Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents
JP2025087716A (ja) 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート
TW201609094A (zh) 治療癌症之新穎方法
FR2527441A1 (fr) Agent pour accroitre l'activite antitumorale d'un agent antitumoral et composition antitumorale le contenant
JP2004518615A (ja) 癌の処置に有用なインドール化合物
JP2014177487A (ja) 慢性リンパ性白血病の処置のためのニロチニブとナイトロジェンマスタードの組み合わせ剤
US5895785A (en) Treatment and prevention of disorders mediated by LA-paf or endothelial cells
EP1385513B1 (fr) Associations pharmaceutiques a base de derives de pyridoindolone et d'agents anticancereux
US20180055915A1 (en) Compositions and methods for treating prostate cancer
US5530023A (en) Production of binding sites for PAF, PAF analogues and PAF antagonists in endothelial cells
US7666905B2 (en) Compositions comprising hepoxilin analogs and their use in the treatment of cancer
JPH11503721A (ja) ベンズアミド誘導体の新規用途
WO2025255237A1 (en) Use of atr inhibitors in combination with radioligand therapy for the treatment of cancer
CN116940365A (zh) 慢性髓性白血病干细胞抑制剂
JP2005520806A (ja) がん治療を改善する併用療法におけるキナゾリノン化合物
EP0868189A1 (en) Antineoplastic methods and compositions employing (+)-fotemustine
CN1207041A (zh) 使用光学纯(－)－福莫司汀抗肿瘤的方法和组合物
AU7229400A (en) Antineoplastic methods and compositions employing (+)-fotemustine
EP0866712A1 (en) Antineoplastic methods and compositions employing optically pure (-)-fotemustine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110510